Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM230 in HER2-related advanced solid tumors
NCT06644300Phase 1Recruiting
- Sponsor
- Biomissile Pharmaceuticals Co., Ltd.
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of BM230 in breast cancer, gastric cancer (GC), colorectal cancer (CRC) and 8 more (2 arms), sponsored by Biomissile Pharmaceuticals Co., Ltd. Primary endpoints: Dose-Limiting Toxicity at 21 days, Adverse Events up to 3 years and 2 more. Started Dec 2024; status: recruiting.
02
Drugs
BM230
03
Conditions
breast cancergastric cancer (GC)colorectal cancer (CRC)non-small cell lung cancer (NSCLC)ovarian cancer
Beyond the preview
Go deeper on NCT06644300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644300.